Foghorn Therapeutics Inc.
FHTXFoghorn Therapeutics Inc. in brief
Foghorn Therapeutics Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. Its market value was $123 M on 28 October 2026, which makes it the 18,011th largest listed company in the world and the 3,413th largest in the USA on this site. In the year to December 2025 it had sales of $31 M and a net loss of $74 M. It employs about 85 people and Adrian Gottschalk is its chief executive. Its largest business segments by sales in 2025 were The (100%). Its shares trade under the symbol FHTX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. is Developing Therapies designed to modulate the chromatin regulatory system company. The company estimated annual revenue is currently 17.8 million USD per year and 85 employees as on 2020. The headquarters is in USA.
Foghorn Therapeutics Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 23 October 2020; shares registered for exchange trading on 19 October 2020.
- 2023
- 💰Record revenue of $34 millionFY2023, the highest of the 6 years on record.
Events of Foghorn Therapeutics Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,433 (Jan 2021) · #2,851 (Jan 2022) · #3,493 (Dec 2022) · #2,951 (Jul 2023) · #3,063 (Jan 2024) · #1,469 (Mar 2026) · #2,719 (Aug 2026) · #3,417 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 4.0×
- Price / book
- —
- Free cash flow yield
- -70.1%
- Net margin
- -240.3%
- Operating margin
- -279.5%
- Return on equity
- —
- Liabilities / assets
- 154.8%
- Net debt
- $-101M
- Revenue growth
- +36.8%
- R&D / revenue
- 276.5%
- Revenue per employee
- $364 K
- Profit per employee
- $-874 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $31M | +36.8% | $-86M | $-74M | -240.3% |
| Dec 2024 | $23M | -33.8% | $-103M | $-87M | -383.3% |
| Dec 2023 | $34M | +77.6% | $-108M | $-98M | -288.1% |
| Dec 2022 | $19M | +1356.8% | $-117M | $-109M | -566.2% |
| Dec 2021 | $1M | +207.0% | $-101M | $-101M | -7675.8% |
| Dec 2020 | $0M | — | $-69M | $-69M | -16000.0% |
| Dec 2019 | — | — | $-51M | $-51M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-86M | $0M | $-86M | $-1.18 | — |
| Dec 2024 | $-100M | $1M | $-101M | $-1.58 | — |
| Dec 2023 | $-118M | $1M | $-119M | $-2.34 | — |
| Dec 2022 | $194M | $1M | $192M | $-2.62 | — |
| Dec 2021 | $-50M | $3M | $-54M | $-2.73 | — |
| Dec 2020 | $-31M | $16M | $-47M | $-6.23 | — |
| Dec 2019 | $-46M | $1M | $-47M | $-12.20 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $84M (+925.0% on a year earlier), net income $58M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Nov 9, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 1, 20268-KCurrent reportRestructuring costs · Regulation FD disclosure
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jun 24, 20268-KCurrent reportShareholder vote
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Apr 30, 2026DEF 14AProxy statement
- Apr 21, 20268-KCurrent reportRegulation FD disclosure · Other events
- Mar 11, 202610-KAnnual report · period to Dec 2025
- Mar 11, 20268-KCurrent reportResults of operations · Regulation FD disclosure
Official filings of Foghorn Therapeutics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $31 M
- Operating income
- $-86 M
- Net income
- $-74 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $198 M
- Total liabilities
- $307 M
- Total equity
- $-109 M
As of December-2025
Top 100 institutional investors in Foghorn Therapeutics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Flagship Pioneering, LLC | 12,674,120 | 0 (0.00%) | 21.14% | $45 M | Nov 16, 2026 |
| 2 | BVF Inc/il | 5,842,000 | 0 (0.00%) | 9.74% | $21 M | Nov 16, 2026 |
| 3 | FMR LLC | 5,546,349 | -159,609 (-2.80%) | 9.25% | $20 M | Nov 10, 2026 |
| 4 | Deerfield Management Company, L.P. | 4,394,367 | 0 (0.00%) | 7.33% | $16 M | Nov 16, 2026 |
| 5 | BlackRock, Inc. | 3,065,236 | +438,404 (+16.69%) | 5.11% | $11 M | Nov 13, 2026 |
| 6 | Raymond James Financial Inc | 2,479,621 | -10,357 (-0.42%) | 4.14% | $9 M | Nov 12, 2026 |
| 7 | Vanguard Capital Management LLC | 1,586,219 | +91,608 (+6.13%) | 2.65% | $6 M | Nov 13, 2026 |
| 8 | Euclidean Capital LLC | 1,573,761 | 0 (0.00%) | 2.62% | $6 M | Nov 16, 2026 |
| 9 | Geode Capital Management, LLC | 861,655 | -49,211 (-5.40%) | 1.44% | $3 M | Nov 6, 2026 |
| 10 | Siren, L.L.C. | 720,720 | 0 (0.00%) | 1.20% | $3 M | Nov 12, 2026 |
| 11 | State Street Corp | 692,290 | -5,179 (-0.74%) | 1.15% | $2 M | Nov 12, 2026 |
| 12 | Jpmorgan Chase & Co | 643,533 | +623,100 (+3049.48%) | 1.07% | $2 M | Nov 12, 2026 |
| 13 | Qube Research & Technologies Ltd | 540,315 | +337,019 (+165.78%) | 0.90% | $2 M | Nov 13, 2026 |
| 14 | Renaissance Technologies LLC | 432,339 | +54,403 (+14.39%) | 0.72% | $2 M | Nov 12, 2026 |
| 15 | Vanguard Portfolio Management LLC | 338,066 | +33,634 (+11.05%) | 0.56% | $1 M | Nov 13, 2026 |
| 16 | Jacobs Levy Equity Management, Inc | 321,284 | +15,850 (+5.19%) | 0.54% | $1 M | Nov 16, 2026 |
| 17 | Northern Trust Corp | 316,432 | +6,657 (+2.15%) | 0.53% | $1 M | Nov 16, 2026 |
| 18 | Candriam S.C.A. | 313,765 | 0 (0.00%) | 0.52% | $1 M | Nov 3, 2026 |
| 19 | Birchview Capital, LP | 282,307 | +370 (+0.13%) | 0.47% | $1 M | Nov 13, 2026 |
| 20 | Vanguard Fiduciary Trust Co | 275,130 | +10,708 (+4.05%) | 0.46% | $1 M | Nov 13, 2026 |
| 21 | Goldman Sachs Group Inc | 234,669 | +70,413 (+42.87%) | 0.39% | $1 M | Nov 16, 2026 |
| 22 | Panagora Asset Management Inc | 227,091 | +51,685 (+29.47%) | 0.38% | $1 M | Nov 12, 2026 |
| 23 | B Group, Inc. | 200,000 | 0 (0.00%) | 0.33% | $1 M | Nov 16, 2026 |
| 24 | Morgan Stanley | 172,839 | +80,743 (+87.67%) | 0.29% | $1 M | Nov 13, 2026 |
| 25 | Ikarian Capital, LLC | 160,000 | New | 0.27% | $1 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Mackenzie Financial Corp | 151,354 | New | 0.25% | $1 M | Nov 2, 2026 |
| 27 | Acadian Asset Management LLC | 151,224 | +112,440 (+289.91%) | 0.25% | $1 M | Nov 9, 2026 |
| 28 | Squarepoint Ops LLC | 137,435 | +7,089 (+5.44%) | 0.23% | $0 M | Nov 9, 2026 |
| 29 | Ameriprise Financial Inc | 128,536 | -430,149 (-76.99%) | 0.21% | $0 M | Nov 16, 2026 |
| 30 | Charles Schwab Investment Management Inc | 127,072 | +17,291 (+15.75%) | 0.21% | $0 M | Nov 16, 2026 |
| 31 | UBS Group AG | 125,524 | +114,293 (+1017.66%) | 0.21% | $0 M | Nov 10, 2026 |
| 32 | SCS Capital Management LLC | 106,980 | 0 (0.00%) | 0.18% | $0 M | Nov 12, 2026 |
| 33 | Citadel Advisors LLC | 106,479 | -52,343 (-32.96%) | 0.18% | $0 M | Nov 16, 2026 |
| 34 | Point72 Asset Management, L.P. | 106,201 | New | 0.18% | $0 M | Nov 16, 2026 |
| 35 | DAFNA Capital Management LLC | 89,659 | -22,200 (-19.85%) | 0.15% | $0 M | Nov 16, 2026 |
| 36 | Palumbo Wealth Management LLC | 88,791 | -2,948 (-3.21%) | 0.15% | $0 M | Nov 13, 2026 |
| 37 | Prudential Financial Inc | 86,998 | New | 0.15% | $0 M | Nov 16, 2026 |
| 38 | Invesco Ltd. | 83,313 | +5,178 (+6.63%) | 0.14% | $0 M | Nov 12, 2026 |
| 39 | Millennium Management LLC | 82,236 | +28,727 (+53.69%) | 0.14% | $0 M | Nov 16, 2026 |
| 40 | HRT Financial LP | 79,961 | New | 0.13% | $0 M | Nov 13, 2026 |
| 41 | Trexquant Investment LP | 79,711 | New | 0.13% | $0 M | Nov 16, 2026 |
| 42 | Bank of New York Mellon Corp | 77,575 | -1,780 (-2.24%) | 0.13% | $0 M | Nov 5, 2026 |
| 43 | Bridgeway Capital Management, LLC | 77,100 | -12,500 (-13.95%) | 0.13% | $0 M | Nov 16, 2026 |
| 44 | Susquehanna International Group, LLP | 75,361 | New | 0.13% | $0 M | Nov 16, 2026 |
| 45 | Empowered Funds, LLC | 70,500 | New | 0.12% | $0 M | Nov 13, 2026 |
| 46 | Gsa Capital Partners LLP | 68,501 | +38,995 (+132.16%) | 0.11% | $0 M | Nov 16, 2026 |
| 47 | Nuveen, LLC | 67,077 | +2,038 (+3.13%) | 0.11% | $0 M | Nov 10, 2026 |
| 48 | Lynx1 Capital Management LP | 61,588 | 0 (0.00%) | 0.10% | $0 M | Nov 16, 2026 |
| 49 | Boothbay Fund Management, LLC | 51,146 | New | 0.09% | $0 M | Nov 16, 2026 |
| 50 | Verdad Advisers, LP | 42,049 | -11,182 (-21.01%) | 0.07% | $0 M | Nov 16, 2026 |
| 51 | Rhumbline Advisers | 41,832 | +2,250 (+5.68%) | 0.07% | $0 M | Nov 10, 2026 |
| 52 | Bank Of America Corp /de/ | 41,488 | +15,385 (+58.94%) | 0.07% | $0 M | Nov 16, 2026 |
| 53 | Engineers Gate Manager LP | 39,539 | New | 0.07% | $0 M | Nov 16, 2026 |
| 54 | AQR Capital Management LLC | 37,375 | -28,864 (-43.58%) | 0.06% | $0 M | Nov 16, 2026 |
| 55 | Price T Rowe Associates Inc /MD/ | 35,194 | +10,716 (+43.78%) | 0.06% | $0 M | Nov 16, 2026 |
| 56 | Graham Capital Management, L.P. | 32,318 | New | 0.05% | $0 M | Nov 16, 2026 |
| 57 | Deutsche Bank AG\ | 32,122 | -4,415 (-12.08%) | 0.05% | $0 M | Nov 6, 2026 |
| 58 | EntryPoint Capital, LLC | 31,568 | +16,085 (+103.89%) | 0.05% | $0 M | Nov 13, 2026 |
| 59 | Public Employees Retirement System Of Ohio | 31,408 | +29,157 (+1295.29%) | 0.05% | $0 M | Nov 16, 2026 |
| 60 | Susquehanna Portfolio Strategies, LLC | 30,438 | New | 0.05% | $0 M | Nov 16, 2026 |
| 61 | Jump Financial, LLC | 30,422 | -5,961 (-16.38%) | 0.05% | $0 M | Nov 13, 2026 |
| 62 | Alliancebernstein L.P. | 29,760 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 63 | Barclays PLC | 28,766 | +9,577 (+49.91%) | 0.05% | $0 M | Nov 6, 2026 |
| 64 | Canada Pension Plan Investment Board | 25,100 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 65 | Atom Investors LP | 24,950 | New | 0.04% | $0 M | Nov 16, 2026 |
| 66 | Stifel Financial Corp | 21,616 | New | 0.04% | $0 M | Nov 12, 2026 |
| 67 | Creative Planning | 20,710 | New | 0.03% | $0 M | Nov 2, 2026 |
| 68 | Quadrature Capital Ltd | 20,700 | New | 0.03% | $0 M | Nov 13, 2026 |
| 69 | Two Sigma Securities, LLC | 18,162 | New | 0.03% | $0 M | Nov 16, 2026 |
| 70 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 17,710 | +888 (+5.28%) | 0.03% | $0 M | Nov 16, 2026 |
| 71 | Two Sigma Investments, LP | 16,627 | +4,182 (+33.60%) | 0.03% | $0 M | Nov 16, 2026 |
| 72 | Simplex Trading, LLC | 15,770 | +13,878 (+733.51%) | 0.03% | $0 M | Nov 4, 2026 |
| 73 | Russell Investments Group, Ltd. | 14,853 | +424 (+2.94%) | 0.02% | $0 M | Nov 6, 2026 |
| 74 | Diversified Trust Co | 14,830 | 0 (0.00%) | 0.02% | $0 M | Nov 6, 2026 |
| 75 | Axq Capital, LP | 14,637 | New | 0.02% | $0 M | Nov 12, 2026 |
| 76 | SEI Investments Co | 14,457 | New | 0.02% | $0 M | Nov 10, 2026 |
| 77 | Prelude Capital Management, LLC | 13,761 | New | 0.02% | $0 M | Nov 16, 2026 |
| 78 | Wells Fargo & Company/mn | 13,427 | -21,874 (-61.96%) | 0.02% | $0 M | Nov 16, 2026 |
| 79 | Steward Partners Investment Advisory, LLC | 13,417 | New | 0.02% | $0 M | Nov 13, 2026 |
| 80 | HSBC Holdings PLC | 13,210 | New | 0.02% | $0 M | Nov 16, 2026 |
| 81 | Vanguard Global Advisers, LLC | 13,005 | +172 (+1.34%) | 0.02% | $0 M | Nov 13, 2026 |
| 82 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 12,793 | +9,917 (+344.82%) | 0.02% | $0 M | Nov 16, 2026 |
| 83 | Centiva Capital, LP | 12,151 | New | 0.02% | $0 M | Nov 13, 2026 |
| 84 | Strs Ohio | 11,700 | +3,100 (+36.05%) | 0.02% | $0 M | Oct 30, 2026 |
| 85 | Manufacturers Life Insurance Company, The | 11,699 | New | 0.02% | $0 M | Nov 13, 2026 |
| 86 | MetLife Investment Management, LLC | 11,374 | New | 0.02% | $0 M | Nov 16, 2026 |
| 87 | Police & Firemen's Retirement System of New Jersey | 11,326 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 88 | XTX Topco Ltd | 11,043 | New | 0.02% | $0 M | Nov 16, 2026 |
| 89 | China Universal Asset Management Co., Ltd. | 10,835 | +1,491 (+15.96%) | 0.02% | $0 M | Oct 28, 2026 |
| 90 | BNP Paribas Financial Markets | 10,482 | +26 (+0.25%) | 0.02% | $0 M | Nov 12, 2026 |
| 91 | Employees Retirement System of Texas | 10,324 | New | 0.02% | $0 M | Nov 10, 2026 |
| 92 | Evelyn Partners Group Ltd | 7,100 | 0 (0.00%) | 0.01% | $0 M | Nov 10, 2026 |
| 93 | Citigroup Inc | 3,388 | -15,156 (-81.73%) | 0.01% | $0 M | Nov 4, 2026 |
| 94 | Ameritas Investment Partners, Inc. | 3,343 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 95 | Mirae Asset Global Investments Co., Ltd. | 3,035 | +409 (+15.58%) | 0.01% | $0 M | Oct 29, 2026 |
| 96 | Legal & General Group Plc | 2,985 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 97 | Tower Research Capital LLC (TRC) | 2,757 | -525 (-16.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 98 | Royal Bank Of Canada | 2,101 | +1,004 (+91.52%) | 0.00% | $0 M | Nov 16, 2026 |
| 99 | New York State Common Retirement Fund | 1,871 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 100 | GF Fund Management Co. LTD. | 1,349 | +108 (+8.70%) | 0.00% | $0 M | Oct 26, 2026 |
Mutual funds holding Foghorn Therapeutics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC | 1.84 M | $8 M | 2.2% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.03 M | $5 M | 1.3% | <0.01% | +0.1% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 896,556 | $4 M | 1.1% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC | 501,007 | $2 M | 0.61% | <0.01% | −1.3% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 428,310 | $2 M | 0.52% | <0.01% | −0.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 396,371 | $2 M | 0.48% | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 342,513 | $2 M | 0.42% | 0.01% | +84% | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 351,578 | $2 M | 0.43% | 0.03% | −46% | May 31, 2026 |
| 🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC | 283,912 | $1 M | 0.35% | <0.01% | −13% | May 31, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 221,798 | $1 M | 0.27% | 0.01% | −0.6% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 188,248 | $1 M | 0.23% | <0.01% | +2.1% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 175,973 | $1 M | 0.21% | <0.01% | +7.1% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 122,329 | $1 M | 0.15% | 0.04% | +39% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 83,000 | $0 M | 0.10% | 0.27% | +22% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 87,961 | $0 M | 0.11% | <0.01% | +20% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 63,923 | $0 M | 0.08% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 62,113 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 53,644 | $0 M | 0.07% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 56,879 | $0 M | 0.07% | <0.01% | +15% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 48,322 | $0 M | 0.06% | <0.01% | +44% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 36,498 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 34,015 | $0 M | 0.04% | 0.01% | +88% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 36,629 | $0 M | 0.04% | <0.01% | +9.4% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 30,000 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I | 28,105 | $0 M | 0.03% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 21,128 | $0 M | 0.03% | <0.01% | +95% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 20,000 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 19,962 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 19,268 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 21,925 | $0 M | 0.03% | <0.01% | +3.1% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 19,208 | $0 M | 0.02% | <0.01% | +4.0% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 17,620 | $0 M | 0.02% | <0.01% | +9.6% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 17,433 | $0 M | 0.02% | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc. | 13,584 | $0 M | 0.02% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 14,497 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 NVIT Multi-Manager Small Company FundNATIONWIDE FUND ADVISORS | 13,298 | $0 M | 0.02% | 0.01% | −27% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 12,800 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 12,971 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC | 11,859 | $0 M | 0.01% | 0.02% | −18% | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 10,810 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 10,683 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 10,814 | $0 M | 0.01% | <0.01% | +65% | Jul 31, 2026 |
| 🇺🇸 NVIT Small Cap Value FundNATIONWIDE FUND ADVISORS | 9,753 | $0 M | 0.01% | 0.02% | −28% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 9,070 | $0 M | 0.01% | <0.01% | +21% | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 8,906 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC | 8,883 | $0 M | 0.01% | <0.01% | −56% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 8,261 | $0 M | 0.01% | 0.02% | +30% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 8,309 | $0 M | 0.01% | <0.01% | +20% | May 31, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 6,629 | $0 M | <0.01% | <0.01% | −4.5% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 6,573 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 6,356 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 5,873 | $0 M | <0.01% | <0.01% | +48% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 5,422 | $0 M | <0.01% | <0.01% | +49% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 5,062 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 4,422 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 4,633 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 4,268 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 4,200 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,958 | $0 M | <0.01% | <0.01% | +102% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 3,375 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 3,636 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 3,340 | $0 M | <0.01% | <0.01% | +33% | Jun 30, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 3,343 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 3,577 | $0 M | <0.01% | <0.01% | +5.9% | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 3,280 | $0 M | <0.01% | 0.01% | +113% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 2,713 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 2,790 | $0 M | <0.01% | <0.01% | +62% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 2,231 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 1,571 | $0 M | <0.01% | <0.01% | +80% | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 1,624 | $0 M | <0.01% | <0.01% | +13% | May 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 1,251 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,282 | $0 M | <0.01% | <0.01% | −38% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,269 | $0 M | <0.01% | <0.01% | −38% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,017 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 763 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC | 742 | $0 M | <0.01% | <0.01% | −5.4% | May 31, 2026 |
| 🇺🇸 TIAA Separate Account VA-1 - Stock Index AccountTeachers Advisors, LLC | 505 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 484 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nuveen Life Stock Index FundTeachers Advisors, LLC | 410 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 385 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 204 | $0 M | <0.01% | <0.01% | +13% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 81 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Foghorn Therapeutics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Adrian GottschalkChief Executive Officer, Director | Giftindirect | -59,208 | — | — | 240,792 | Form 4 |
| filed | Adrian GottschalkChief Executive Officer, Director | Giftindirect | +59,208 | — | — | 270,912 | Form 4 |
| filed | Adrian GottschalkChief Executive Officer, Director | Giftindirect | -47,497 | — | — | 0 | Form 4 |
| filed | Adrian GottschalkChief Executive Officer, Director | Giftindirect | +47,497 | — | — | 211,704 | Form 4 |
| filed | Adrian GottschalkChief Executive Officer, Director | Giftindirect | -300,000 | — | — | 511,704 | Form 4 |
| filed | Adrian GottschalkChief Executive Officer, Director | Giftindirect | +300,000 | — | — | 511,704 | Form 4 |
| filed | Adrian GottschalkChief Executive Officer, Director | Giftindirect | -197,906 | — | — | 511,704 | Form 4 |
| filed | Adrian GottschalkChief Executive Officer, Director | Giftindirect | +197,906 | — | — | 511,704 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Foghorn Therapeutics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-10-01 10:55 UTC, code T3, resumed 11:30 UTC
- 2024-12-16 11:55 UTC, code T3, resumed 12:30 UTC
Fails to deliver
- : 2,177 shares at $2.05
- : 1,514 shares at $1.85
- : 14,493 shares at $2.92
- : 51 shares at $3.52
- : 83 shares at $5.69
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Foghorn Therapeutics Inc. scorecard#
Passes 7 of the 19 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✓Price to sales below its peers' median4.0×Price to sales 4.0× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-70.1%Free cash flow is -70.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 6
- ✓Revenue grew in the newest year36.8%Revenue up 36.8% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years17.1%17.1% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median17.1%17.1% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.18 vs -1.58Diluted EPS -1.18 in fiscal 2025 against -1.58 the year before (report's currency).
- ✗Net income higher than five years earlier-$74 M-$74 M in fiscal 2025 against -$69 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability1 of 4
- ✗Profitable in the newest year-$74 MNet income -$74 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-279.5%-279.5% against Biotechnology's median of -60.5% (243 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-279.5%-279.5% in fiscal 2025 against -609.2% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.7×Current ratio 2.73 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-4.89Z-score -4.89 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year14.7%Diluted shares up 14.7% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Foghorn Therapeutics Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -279.5% | -60.5% | |
| Net margin | -240.3% | -68.9% | |
| Revenue growth, 3 years a year | 17.1% | 12.9% | |
| Revenue growth | 36.8% | 15.8% | |
| Free cash flow margin | -278.7% | -61.5% |
1of 7on the Piotroski tests of financial strength
- Net loss of $74 million, the 7th loss-making year in a row.
- Free cash flow was negative: -$86 million.
- The share count rose 14.7% in the year.
- Shareholders' equity is negative: -$108 million.
Foghorn Therapeutics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 31+36.8%100% | 23−33.8%100% | 34+77.6%100% | 19+1358%100% | 1.3+207%100% | 0.4—100% | — | |
| Research and development | 85−9.6%277% | 95−13.8%418% | 110+3.9%321% | 106+31.5%549% | 80+39.2%6090% | 58+30.1%13422% | 44—— | |
| General and administrative | 28−2.9%89.1% | 28−12.4%125% | 32+5.3%94.8% | 31+41.5%160% | 22+93.2%1647% | 11+67.3%2615% | 6.7—— | |
| Operating expenses | 117−6.4%379% | 125−11.8%554% | 142+4.2%416% | 136+33.6%709% | 102+48.0%7737% | 69+35.0%16037% | 51—— | |
| Operating income | −86—−279% | −103—−454% | −108—−316% | −117—−609% | −101—−7637% | −69—−15937% | −51—— | |
| Interest expense and finance costs | — | — | — | — | 1.9+94.7%145% | 1.0+81.3%228% | 0.5—— | |
| Other non-operating income (expense) | 12−24.6%39.2% | 16+17.2%71.1% | 14+66.0%40.1% | 8.3—42.9% | −0.6—−44.4% | −0.3—−62.6% | −0.0—— | |
| Income before tax | — | −87—−383% | −94—−276% | −109—−566% | — | — | — | |
| Income tax | 0—0.0% | 0−100%0.0% | 4.2—12.4% | 0—0.0% | — | 0—0.0% | 0—— | |
| Net income including minority interests | — | — | — | — | — | −69—−16000% | −51—— | |
| Net income attributable to shareholders | −74—−240% | −87—−383% | −98—−288% | −109—−566% | −101—−7682% | −69—−16000% | −51—— | |
| Earnings per share, basic | -1.18—— | -1.58—— | -2.34—— | -2.62—— | -2.73—— | -6.23—— | -12.20—— | |
| Earnings per share, diluted | -1.18—— | -1.58—— | -2.34—— | -2.62—— | -2.73—— | -6.23—— | -12.20—— | |
| Shares, weighted average (basic) | 63+14.7%— | 55+30.8%— | 42+0.9%— | 42+11.9%— | 37+236%— | 11—— | — | |
| Shares, weighted average (diluted) | 63+14.7%— | 55+30.8%— | 42+0.9%— | 42+11.9%— | 37+236%— | 11+164%— | 4.2—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 81+45.8%40.8% | 55−31.0%19.5% | 80+53.9%28.1% | 52−48.4%12.9% | 101+9.0%19.5% | 93+519%36.3% | 15—67.1% | |
| Other current assets | 3.1−47.2%1.6% | 5.9−4.4%2.1% | 6.1+9.3%2.1% | 5.6+6.2%1.4% | 5.3+7.2%1.0% | 4.9+261%1.9% | 1.4—6.1% | |
| Current assets | 163−34.6%82.4% | 250+3.9%87.9% | 240−31.7%84.0% | 351−23.5%86.8% | 460+141%88.4% | 191+1029%74.6% | 17—75.6% | |
| Property, plant and equipment | 1.9−80.8%1.0% | 10.0−23.1%3.5% | 13−15.4%4.5% | 15−12.8%3.8% | 18−10.1%3.4% | 20+628%7.6% | 2.7—12.0% | |
| Right-of-use (leased) assets | 31+36.7%15.6% | 23−24.4%8.0% | 30−12.1%10.5% | 34−11.5%8.4% | 39−10.0%7.4% | 43+4056%16.7% | 1.0—4.6% | |
| Total assets | 198−30.2%100% | 284−0.7%100% | 286−29.4%100% | 405−22.1%100% | 520+103%100% | 256+1044%100% | 22—100% | |
| Accounts payable | 4.3+12.7%2.2% | 3.8−39.5%1.3% | 6.3+15.6%2.2% | 5.4+41.8%1.3% | 3.8+3.8%0.7% | 3.7+7.0%1.4% | 3.4—15.4% | |
| Debt due within a year | — | — | — | — | — | 0−100%0.0% | 4.2—18.6% | |
| Current liabilities | 60−10.8%30.2% | 67+14.6%23.6% | 58+5.9%20.4% | 55+13.4%13.6% | 49+158%9.4% | 19+49.0%7.4% | 13—56.6% | |
| Long-term debt | — | — | — | — | 0−100%0.0% | 20r20+79.3%7.7% | 11—49.1% | |
| Lease liabilities (non-current) | 40+43.8%20.4% | 28−23.2%9.9% | 37−19.7%12.8% | 46−11.3%11.2% | 51−12.0%9.9% | 58+37073%22.8% | 0.2—0.7% | |
| Total liabilities | 307−7.0%155% | 330−9.3%116% | 363−10.3%127% | 405−4.3%100.0% | 423+287%81.4% | 109+359%42.8% | 24—107% | |
| Retained earnings | −632—−319% | −558—−197% | −472—−165% | −373—−92.2% | −264—−50.8% | −163—−63.7% | −94—−421% | |
| Shareholders' equity | −109—−54.8% | −46—−16.0% | −77−69020%−27.0% | 0.1−99.9%0.0% | 97−33.7%18.6% | 146—57.2% | −88—−394% | |
| Total liabilities and equity | 198−30.2%100% | 284−0.7%100% | 286−29.4%100% | 405−22.1%100% | 520+103%100% | 256+1044%100% | 22—100% | |
| Shares outstanding | 57+1.9%— | 56+31.5%— | 42+1.1%— | 42+1.2%— | 41+12.3%— | 37+655%— | 4.9—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 3.3+6.8%10.8% | 3.1−9.6%13.8% | 3.5+3.9%10.1% | 3.3+2.9%17.3% | 3.2+143%245% | 1.3+91.5%309% | 0.7—— | |
| Share-based compensation | 10−12.6%33.6% | 12−26.5%52.6% | 16+12.9%47.4% | 14+71.0%74.6% | 8.4+183%636% | 3.0+74.8%689% | 1.7—— | |
| Cash from operating activities | −86—−279% | −100—−444% | −118−161%−346% | 194—1007% | −50—−3810% | −31—−7276% | −46—— | |
| Capital expenditure | −0.1—−0.2% | −0.9—−4.0% | −1.2—−3.6% | −1.2—−6.3% | −3.3—−251% | −16—−3763% | −1.0—— | |
| Cash from investing activities | 112—362% | −30−121%−132% | 144—423% | −244−775%−1271% | 36—2742% | −109—−25329% | −1.0—— | |
| Shares issued | — | 103—457% | 0—0.0% | — | — | — | — | |
| Cash from financing activities | 1.0−99.0%3.3% | 105+5830%466% | 1.8+0.9%5.2% | 1.8−92.1%9.2% | 22−89.7%1700% | 217+807%50575% | 24—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 112+357%100% | 84+925%100% | 16+113%100% | 3.3−45.1%100% | 9.2*+224%100% | 8.2+4.4%100% | 7.6+9.7%100% | 6.0+17.9%100% | 2.9*−50.5%100% | 7.8—100% | 6.9—100% | 5.1—100% | 5.8*—100% | |
| Research and development | 78−7.5%69.3% | 19−5.8%22.5% | 19−15.0%115% | 18−15.6%559% | 22*+7.5%238% | 20−19.0%245% | 22−8.4%288% | 22−15.3%363% | 21*−15.3%718% | 25—316% | 24—345% | 26—506% | 24*—420% | |
| General and administrative | 26−5.8%22.8% | 5.8−12.9%6.9% | 6.4−7.4%39.5% | 6.6−9.1%201% | 6.8*+7.0%73.5% | 6.7−4.6%81.6% | 6.9−6.3%90.8% | 7.2−6.1%122% | 6.4*−9.5%222% | 7.0—89.3% | 7.3—106% | 7.7—153% | 7.0*—122% | |
| Operating expenses | 110−1.2%97.9% | 27+0.9%32.2% | 25−13.2%155% | 25−13.9%760% | 33*+23.3%358% | 27−15.8%327% | 29−14.5%379% | 29−13.2%485% | 27*−14.0%941% | 32—405% | 34—487% | 33—658% | 31*—541% | |
| Operating income | 2.4—2.1% | 57—67.8% | −8.8—−54.8% | −22—−660% | −24*—−258% | −19—−227% | −21—−279% | −23—−385% | −24*—−841% | −24—−305% | −27—−387% | −28—−558% | −25*—−441% | |
| Other non-operating income (expense) | 7.0−51.1%6.3% | 1.5−43.0%1.8% | 1.6−48.9%10.0% | 1.7−58.4%52.0% | 2.2*−50.8%23.9% | 2.7−43.9%32.5% | 3.2−13.5%41.8% | 4.1+28.4%68.5% | 4.5*+34.9%158% | 4.7—60.6% | 3.7—53.0% | 3.2—62.9% | 3.3*—57.9% | |
| Income before tax | — | — | — | — | — | — | — | — | −20*—−683% | −19—−245% | −23—−334% | −25—−495% | −22*—−383% | |
| Income tax | — | — | — | — | — | — | — | — | 0*−100%0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 2.0*—34.4% | |
| Net income attributable to shareholders | 9.4—8.4% | 58—69.6% | −7.2—−44.7% | −20—−608% | −22*—−234% | −16—−194% | −18—−237% | −19—−316% | −20*—−683% | −19—−245% | −23—−334% | −25—−495% | −24*—−418% | |
| Earnings per share, basic | — | 0.81—— | -0.10—— | -0.29—— | — | -0.25—— | -0.28—— | -0.30—— | — | -0.31—— | -0.45—— | -0.59—— | — | |
| Earnings per share, diluted | — | 0.80—— | -0.10—— | -0.29—— | — | -0.25—— | -0.28—— | -0.30—— | — | -0.31—— | -0.45—— | -0.59—— | — | |
| Shares, weighted average (basic) | 71+13.4%— | 71+13.4%— | 71+12.1%— | 70+10.6%— | — | 63+0.7%— | 63+22.1%— | 63+48.1%— | — | 63—— | 52—— | 42—— | — | |
| Shares, weighted average (diluted) | 73+15.2%— | 73+15.2%— | 71+12.1%— | 70+10.6%— | — | 63+0.7%— | 63+22.1%— | 63+48.1%— | — | 63—— | 52—— | 42—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 80—42.1% | 80−10.1%42.1% | 68−6.2%33.5% | 88+43.6%39.5% | 81+45.8%40.8% | 89+54.9%43.6% | 73−47.8%32.1% | 61−23.0%23.6% | 55−31.0%19.5% | 58—18.7% | 139—42.3% | 79—31.1% | 80—28.1% | |
| Other current assets | 2.1—1.1% | 2.1−19.2%1.1% | 2.5−37.3%1.2% | 3.2−34.1%1.4% | 3.1−47.2%1.6% | 2.6−32.5%1.3% | 3.9−11.6%1.7% | 4.8−0.6%1.9% | 5.9−4.4%2.1% | 3.8—1.2% | 4.4—1.4% | 4.9—1.9% | 6.1—2.1% | |
| Current assets | 158—82.9% | 158−14.0%82.9% | 170−16.6%83.6% | 188−16.6%84.6% | 163−34.6%82.4% | 184−32.1%89.8% | 204−29.6%90.1% | 225+6.6%87.1% | 250+3.9%87.9% | 271—88.0% | 290—88.1% | 212—82.9% | 240—84.0% | |
| Property, plant and equipment | 1.3—0.7% | 1.3−85.1%0.7% | 1.5−84.3%0.7% | 1.7−83.5%0.8% | 1.9−80.8%1.0% | 8.7−17.6%4.2% | 9.5−11.6%4.2% | 10−15.1%4.0% | 10.0−23.1%3.5% | 11—3.4% | 11—3.3% | 12—4.8% | 13—4.5% | |
| Right-of-use (leased) assets | 29—15.4% | 29+188%15.4% | 30+174%14.7% | 30+43.4%13.7% | 31+36.7%15.6% | 10−57.7%5.0% | 11−57.3%4.8% | 21−25.7%8.2% | 23−24.4%8.0% | 24—7.8% | 25—7.8% | 29—11.2% | 30—10.5% | |
| Total assets | 191—100% | 191−6.8%100% | 203−10.1%100% | 222−14.1%100% | 198−30.2%100% | 205−33.5%100% | 226−31.1%100% | 259+1.4%100% | 284−0.7%100% | 308—100% | 329—100% | 255—100% | 286—100% | |
| Accounts payable | 2.2—1.1% | 2.2−32.3%1.1% | 3.2−3.5%1.6% | 3.3−18.5%1.5% | 4.3+12.7%2.2% | 3.2−6.9%1.6% | 3.3−31.0%1.5% | 4.1−27.7%1.6% | 3.8−39.5%1.3% | 3.5—1.1% | 4.8—1.5% | 5.6—2.2% | 6.3—2.2% | |
| Current liabilities | 37—19.5% | 37−56.1%19.5% | 51−35.0%24.9% | 64−9.7%29.0% | 60−10.8%30.2% | 85+49.7%41.5% | 78+52.9%34.4% | 71+37.0%27.6% | 67+14.6%23.6% | 57—18.4% | 51—15.5% | 52—20.4% | 58—20.4% | |
| Lease liabilities (non-current) | 40—21.0% | 40+154%21.0% | 40+130%19.8% | 40+55.9%18.1% | 40+43.8%20.4% | 16−47.9%7.7% | 18−37.6%7.7% | 26−25.0%9.9% | 28−23.2%9.9% | 30—9.8% | 28r33—8.5% | 34—13.5% | 37—12.8% | |
| Total liabilities | 205—107% | 205−30.4%107% | 284−6.1%140% | 299−6.8%134% | 307−7.0%155% | 295−12.5%144% | 303−11.7%134% | 320−9.1%124% | 330−9.3%116% | 337—109% | 343—104% | 352—138% | 363—127% | |
| Retained earnings | −601—−315% | −601—−315% | −660—−324% | −652—−294% | −632—−319% | −611—−298% | −595—−263% | −577—−223% | −558—−197% | −539—−175% | −520—−158% | −497—−195% | −472—−165% | |
| Shareholders' equity | −14—−7.4% | −14—−7.4% | −81—−39.8% | −76—−34.4% | −109—−54.8% | −90—−43.7% | −77—−33.9% | −62—−23.8% | −46—−16.0% | −28—−9.2% | −14—−4.4% | −97—−38.2% | −77—−27.0% | |
| Total liabilities and equity | 191—100% | 191−6.8%100% | 203−10.1%100% | 222−14.1%100% | 198−30.2%100% | 205−33.5%100% | 226−31.1%100% | 259+1.4%100% | 284−0.7%100% | 308—100% | 329—100% | 255—100% | 286—100% | |
| Shares outstanding | 60—— | 60+6.0%— | 59+5.2%— | 59+5.4%— | 57+1.9%— | 57+1.7%— | 56+0.9%— | 56+30.8%— | 56+31.5%— | 56—— | 55—— | 43—— | 42—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.4−57.5%1.3% | 0.2−77.8%0.2% | 0.2−77.8%1.2% | 0.2−71.2%7.3% | 0.8*+5.4%8.7% | 0.9+28.6%11.0% | 0.9+12.5%11.9% | 0.8−1.0%13.9% | 0.8*−10.7%26.6% | 0.7—9.0% | 0.8—11.6% | 0.8—16.5% | 0.9*—14.8% | |
| Share-based compensation | 9.7−8.9%8.6% | 2.5−7.8%3.0% | 2.6−6.7%15.9% | 2.4−11.5%72.9% | 2.2*−9.7%24.2% | 2.7−9.4%33.5% | 2.7−13.7%36.2% | 2.7−16.5%45.2% | 2.5*−18.6%86.9% | 3.0—38.7% | 3.2—46.0% | 3.2—63.8% | 3.1*—52.9% | |
| Cash from operating activities | −84—−74.6% | −18*—−21.8% | −18*—−111% | −25—−773% | −22*—−241% | −19*—−231% | −21*—−278% | −24—−403% | −25*—−859% | −21*—−269% | −26*—−371% | −29—−581% | −28*—−477% | |
| Capital expenditure | −0.1—−0.1% | −0.0*—−0.0% | −0.1*—−0.3% | 0—0.0% | 0*—0.0% | 0*—0.0% | −0.0*—−0.3% | −0.0—−0.5% | −0.5*—−16.8% | −0.3*—−4.0% | −0.0*—−0.2% | −0.1—−2.0% | −0.0*—−0.6% | |
| Cash from investing activities | 17−86.2%14.9% | 24*−32.0%29.0% | −3.0*−109%−18.5% | −18−160%−542% | 13*−40.6%143% | 36*—436% | 34*—448% | 29+8.5%494% | 22*−40.4%780% | −61*—−785% | −18*—−261% | 27—537% | 37*—648% | |
| Shares issued | — | — | 0*—0.0% | 50—1530% | — | 0*—0.0% | 0*—0.0% | 0—0.0% | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | |
| Cash from financing activities | 57+12592%50.5% | 6.3*+12708%7.5% | −0.0*−109%−0.1% | 50+35707%1523% | 0.6*+14425%6.3% | 0.0*−95.3%0.6% | 0.3*−99.8%3.4% | 0.1−88.1%2.3% | 0.0*−97.8%0.1% | 1.1*—13.5% | 103*—1498% | 1.2—23.1% | 0.2*—3.2% | |
| Change in cash | — | — | — | — | — | — | — | — | — | −81*—−1041% | 60*—867% | −1.1—−21.4% | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Foghorn Therapeutics Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Business segments
- The$31 M100%+37%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Foghorn Therapeutics Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Gottshalk | $2.4 M | $3.1 M | $1.2 M | $84 |
| 2024Adrian Gottschalk | $1.6 M | $2.4 M | $1.7 M | $73 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Foghorn Therapeutics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Restructuring 1 · Directors and officers 5 · Material agreement 1 · Agreement ended 1 · Shareholder vote 2 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026
H-1B hiring at Foghorn Therapeutics Inc.#
9 labor condition applications certified in fiscal 2026 for 9 positions, at a median wage of $135 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior ScientistMolecular and Cellular Biologists | 3 | $135 K |
| Principal Research AssociateChemists | 2 | $106 K |
| ScientistChemists | 2 | $129 K |
| Senior Scientist, BioinformaticsBioinformatics Scientists | 2 | $135 K |
Where: Watertown, MA 9
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 9 | 9 | $135 K | 9 |
| FY2025 | 1 | 1 | $126 K | 1 |
| FY2023 | 6 | 6 | $125 K | 6 |
| FY2022 | 8 | 8 | $125 K | 8 |
| FY2021 | 3 | 3 | $122 K | 3 |
| FY2020 | 2 | 2 | $61 K | 3 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Foghorn Therapeutics, Inc.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 40% of workforce | Restructuring planSEC 8-K | “In connection with this decision, the Company announced a reduction in its workforce by approximately 40% of its current workforce.” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Foghorn Therapeutics Inc. compares in Biotechnology
- Market cap$123 M · higher than 39% of 726
- Revenue$31 M · higher than 54% of 647
- Net margin-240.3% · higher than 24% of 408
- Revenue growth36.8% · higher than 69% of 438
- Price / sales4.0× · lower than 68% of 339
- FCF yield-70.1% · higher than 17% of 449
- 🇺🇸 Anavex Life Sciences Corp.$123 M
- 🇹🇼 Mycenax Biotech Inc.$124 M
- 🇺🇸 Humacyte, Inc.$125 M
- 🇺🇸 Immunic, Inc.$121 M
- 🇺🇸 Nkarta, Inc.$125 M
- 🇹🇼 Medigen Biotechnology Corp.$120 M
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Foghorn Therapeutics Inc.🇺🇸 | $123 M | — | -240.3% | +36.8% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on August 2020
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Foghorn Therapeutics Inc.? Verify and update this profile — free
Show Foghorn Therapeutics Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.